Zenabis Global — Investor Presentation (August 2019)
36 slides from Zenabis Global's investor presentation, Aug 21, 2019
Slide 1: Corporate Presentation
Corporate Presentation August 21, 2019 TSX: ZENA TSX: ZENA
Slide 2: Disclaimers
Disclaimers IMPORTANT: YOU MUST READ THE FOLLOWING BEFORE CONTINUING. The information contained in this document has been prepared by Zenabis Global Inc. (“Zenabis” or the “Company”). The information contained in this document (a) is provided as at the date hereof and is subject to change without no
Slide 3: Where We Came From
WHERE WE CAME FROM… Zenabis was formed in January 2019 after the reverse-takeover of Bevo Agro Inc. by Sun Pharm Investments Ltd. ▪ Broad depth of experience ranging from successfully developing businesses in highly regulated industries to operating one of the largest fresh herb and produce companie
Slide 4: Who We Are Today
WHO WE ARE TODAY Zenabis is a licensed cannabis producer with four existing licensed production facilities, significant existing capacity and domestic distribution, and a management team committed to completing facility conversion and developing an international business. Facility Footprint & Licens
Slide 5: Our Facilities
OUR FACILITIES 1. Zenabis Atholville 2. Zenabis Langley1 3. Zenabis Stellarton 4. Zenabis Delta Atholville, New Brunswick Langley, British Columbia Stellarton, Nova Scotia Delta, British Columbia ▪ 380,000 sq. ft. indoor facility ▪ 2,100,000 sq. ft. greenhouse ▪ 255,000 sq. ft. indoor facility ▪ 25,
Slide 6: Production Footprint
PRODUCTION FOOTPRINT Zenabis Zenabis Zenabis Zenabis Zenabis Pitt Zenabis Atholville Langley Stellarton Delta Meadows Aldergrove Atholville, NB Langley, BC Stellarton, NS Delta, BC Pitt Meadows, BC Aldergrove, BC Parcel Size 871,000 sq. ft. 4,279,000 sq. ft. 547,000 sq. ft. 51,000 sq. ft. 871,000 sq
Slide 7: Production – Atholville
PRODUCTION – ATHOLVILLE Between October 2018 and June 2019 Zenabis harvested a total of 4,766 kg of dried cannabis at Zenabis Atholville. The amount harvested has exceeded the design capacity1 of the flower rooms by 21.0% over the nine-month period and 25.0% in 2019. Actual Harvest Weight vs. Design
Slide 8: Comparable Production Metrics
COMPARABLE PRODUCTION METRICS1 (kg) Current Licensed Annual Production Capacity 200,000 180,000 2 160,000 54,000kg 143,200kg 140,000 120,000 100,000 80,000 60,000 40,000 20,000 - 2 VIVO TGOD Supreme Village Farms Cronos CannTrust Zenabis Sundial OrganiGram Aphria Zenabis Aurora Expected Capacity Und
Slide 9: Comparable Production Multiples
COMPARABLE PRODUCTION MULTIPLES1 Current Licensed Annual Production Capacity Metrics CRON ACB TGOD VFF SNDL APHA OGI FIRE VIVO TRST ZENA Enterprise Value2 3,014 8,066 812 885 1,431 2,030 1,008 520 75 353 365 ($m) Current Capacity 40,150 175,300 17,500 37,500 60,000 115,000 61,000 33,580 8,000 50,000
Slide 10: Brands
BRANDS Existing Brands Type: Medical brand Type: Premium recreational brand Type: Niche recreational brand Sales Channels: Online Sales Channels: Online and brick- Sales Channels: Online and brick- and-mortar and-mortar Current Products: Dried cannabis Current Products: N/A Current Products: Pre-rol
Slide 11: Product Portfolio
PRODUCT PORTFOLIO Current Products Dried Flower Pre-Rolls Oils Tinctures and Sprays Softgel Capsules Currently Intended Future Products1 Edibles Flavoured and Sparkling Water Health and Beauty Topicals Kombucha Other Non-Alcoholic Beverages Vapes and Concentrates DIY Kits TSX: ZENA 10 Note: 1) Subje
Slide 12: Domestic Partnerships and Distribution Channels
DOMESTIC PARTNERSHIPS AND DISTRIBUTION CHANNELS Zenabis has developed a diverse set of partnerships and relationships with provinces1, distributors, pharmacies and First Nations. Definitive Supply agreement agreement for medical cannabis primarily for oil products Yukon Liquor Corporation (“YLC”) Su
Slide 13: Growing International Distribution
GROWING INTERNATIONAL DISTRIBUTION Germany Europe Malta Zenabis has entered into a binding term sheet for a Zenabis has signed a non-binding letter of intent with a Zenabis has signed a non-binding letter of intent to three-year supply arrangement with a German European distributor to supply 2,400kg
Slide 14: Recent Developments
RECENT DEVELOPMENTS Zenabis continues to deliver on its promises to investors by increasing its available capital, securing additional distribution channels, expanding its licensed production footprint, and achieving success in cultivation. ▪ Zenabis signed definitive documentation for $25.0m in new
Slide 15: Major Achievements
MAJOR ACHIEVEMENTS Secured $25.0m Additional Debt Financing Secured Cultivation License at Zenabis Langley Secured $40.0m of Non-Dilutive Financing via Financing Milestones Supply Agreements Licensing Milestones Secured Industrial Hemp License Corporate Development Milestones Secured Approvals for A
Slide 16: Management (1/2)
MANAGEMENT | (1/2) Andrew Grieve Leo Benne Mike Smyth Chief Executive Officer Chief Growing Officer Chief Financial Officer ▪ Experienced financial executive, entrepreneur ▪ Formerly Vice President and Director of Bevo ▪ Extensive experience in corporate finance, and principal investor (>18 investme
Slide 17: Management (2/2)
MANAGEMENT | (2/2) Kevin Coft Dr. Zeid Mohamedali, MD, PhD Laura DiFelice Chief Facilities Officer Chief Medical Officer Director, People and Culture ▪ An operational and supply chain professional ▪ Over 20 years of experience in medical ▪ A highly skilled human resources professional with over 30 y
Slide 18: Board of Directors
BOARD OF DIRECTORS Monty Sikka Andrew Grieve Leo Benne Co-Founder, Director and Chairman Chief Executive Officer and Director Chief Growing Officer and Director ▪ Co-founder of Zenabis ▪ Experienced financial executive, entrepreneur ▪ Formerly Vice President and Director of Bevo ▪ As President of th
Slide 19: Management & Key Shareholder Alignment
MANAGEMENT & KEY SHAREHOLDER ALIGNMENT CEO Compensation Alignment CEO does not receive cash compensation unless two hurdles are met by the company: 1. Earnings (as measured by EBITDA1 or EPS) above a certain measure2 in 2020 2. Share price over the four quarters commencing June 2021 is greater than
Slide 20: Selected Financial Information
SELECTED FINANCIAL INFORMATION Selected Financial Metrics Value Ownership Breakdown Adjusted Cash $62m1 Debt $150m1 Market Capitalization $285m2 Enterprise Value $365m2 48.2% 51.8% Financial Results Q2 20193 Insiders & Founders Other Investors Gross Revenue $26.5m Net Revenue $25.0m Net Loss ($18.5m
Slide 21: Corporate Highlights
CORPORATE HIGHLIGHTS 100 Years of Industrial-Scale Cultivation Expertise Extensive Industry Expertise and Proven Execution Capabilities Extensive Domestic Distribution Network Highly Recognizable Brands Four Licenced Facilities Low Production Costs at Scale Relationships and Partnerships with Govern
Slide 22: Contact Us
TSX: ZENA Contact Us invest@zenabis.com zenabis.com TSX: ZENA
Slide 23: Appendix A – Facilities
Appendix A – Facilities TSX: ZENA
Slide 24: Zenabis Atholville
ZENABIS ATHOLVILLE Zenabis Atholville is Zenabis’ largest indoor facility. This facility is expected to produce 46,300kg 1 of dried cannabis equivalent per year upon full buildout. Facility Details Description Location Atholville, New Brunswick Type and Size 380k sq. ft. indoor cannabis Substantiall
Slide 25: Zenabis Langley
ZENABIS LANGLEY Zenabis Langley is one of the largest greenhouses in Canada with advanced propagation technology. The facility is expected to produce 426,000kg1 of dried cannabis equivalent per year upon full buildout. Facility Details Description Location Langley, British Columbia Type and Size 2.1
Slide 26: Zenabis Stellarton
ZENABIS STELLARTON Zenabis Stellarton is a licensed indoor facility located in Stellarton, Nova Scotia. The facility can produce 18,500kg 1 of dried cannabis equivalent per year upon full buildout. Facility Details Description Location Stellarton, Nova Scotia Type and Size 255k sq. ft. indoor cannab
Slide 27: Zenabis Delta
ZENABIS DELTA Zenabis Delta is an indoor facility located in the Greater Vancouver Area. This facility is expected to be used primarily as a lab for extraction and R&D activities. Facility Details Description Location Delta, British Columbia Type and Size 25k sq. ft. Indoor cannabis Status Lab conve
Slide 28: 2019 Harvest Schedule
2019 HARVEST SCHEDULE The following highlights the forecast harvest schedule for Zenabis’ existing licensed facilities 1. This forecast assumes Part 1 of Zenabis Langley Site A is licensed and assumes Zenabis Atholville is fully licensed by August 2019. Monthly Harvest Schedule for Existing Licensed
Slide 29: Increasing Licensed Production Capacity
INCREASING LICENSED PRODUCTION CAPACITY Zenabis Zenabis Zenabis Date Zenabis Delta Total Atholville Langley Stellarton Capacity at RTO January 8, 2019 5,600kg - - 100kg 5700kg Phase 1B License Amendment January 11, 2019 +1,600kg - - - +1,600kg Stellarton Cultivation License March 1, 2019 - - +800kg
Slide 30: Appendix B – Financial Information
Appendix B – Financial Information TSX: ZENA
Slide 31: Capitalization
CAPITALIZATION The following outlines the capitalization of Zenabis. Capitalization Enterprise Value Fully Diluted Shares Outstanding1 Value Enterprise Value Calculation Value Basic Shares Outstanding 208,623,741 Basic Shares Outstanding 208,623,741 Plus: Options 19,048,395 Plus: ITM Options1 2,677,
Slide 32: Debt Outstanding
DEBT OUTSTANDING The following outlines Zenabis’ debt outstanding. Debt Summary Principal Amount as Principal Amount as Facility Description of June 30, 2019 of August 21, 2019 ▪ Unsecured convertible debentures with interest rate of 6.0% Unsecured Convertible ▪ Convertible into Zenabis shares at $3
Slide 33: Appendix C – Other Information
Appendix C – Other Information TSX: ZENA
Slide 34: Performance Ratio Calculation Description
PERFORMANCE RATIO CALCULATION DESCRIPTION1 The following outlines the approach that Zenabis utilizes to calculate its performance relative to design capacity (the Performance Ratio defined below). ▪ Zenabis prepared the design capacity of each of its facilities, as disclosed in the Management Inform
Slide 35: Adjusted EBITDA Calculation
ADJUSTED EBITDA CALCULATION The following outlines the calculation to arrive at adjusted EBITDA. Adjusted EBITDA Calculation Q2 20191 Q1 20192 Net Loss (18,498,388) (4,005,815) Plus: Realized Fair Value Amounts Included in Inventory Sold 10,013,747 3,402,319 Less: Unrealized Gain on Changes in Fair
Slide 36: Comparable Metrics Sources
COMPARABLE METRICS SOURCES ▪ Canopy. Canopy MD&A dated February 14, 2018 and June 21, 2019. ▪ Aurora. Aurora MD&A dated May 14, 2019. ▪ Aphria. Aphria MD&A dated April 15, 2019 and August 1, 2019. ▪ Tilray. Tilray MD&A dated August 13, 2019. ▪ Emerald. Emerald MD&A dated May 30, 2019. ▪ Hydropotheca